Contributor Profile
Timmy Davis
Director of Psychedelic Policy and Regulation at the Centre for Evidence Based Drug Policy (CEBDP), Policy Director and Co-founder of the Psilocybin Access Rights (PAR)
Areas of Focus
Drug policy — Psilocybin, psilocybin therapy — Psychedelic therapy access — Psychedelic policy and regulation
Professional Background
Timmy Davis is director of Psychedelic Policy and Regulation at the Centre for Evidence-Based Drug Policy (CEBDP) through whom he co-founded and runs the Feilding Commission. He is the founder of The Psychedelic Experience Clinic and also policy director and co-founder of the Psilocybin Access Rights (PAR) campaign and a trainee at the Site for Contemporary Psychoanalysis.
Publications
Timmy co-authored a chapter entitled The Feminine Enshadowed: the Role of Psychedelics in Deconstructing the Gender Binary in the book Psychedelic Mysteries of the Feminine (2019), The Medicinal Use of Psilocybin: Reducing Restrictions on Research and Treatment (2020) and Kava: Honoured in the Pacific, Banned in the UK (2026).
He also authored New, Strange, Odd and Weird Perceptions – A Lacanian Approach to Psychedelic Experience (Lacunae, 2020), THOU ART NOT THAT – Towards a Psychoanalytic Understanding of the Bad Trip (Breaking Convention, 2022) and “Undreamt of possibilities” a genealogy of ‘psychedelic’ therapeutics – or the drugs work, but how? (Breaking Convention, 2025).
Personal Links
Education
He graduated from Birkbeck, University of London with an MA in Psychoanalytic Studies and with a BA Hons in Philosophy and Religious Studies from the University of Kent, where he was president of the psychedelic society for three years. He has provided psychological support on the psilocybin for treatment-resistant depression trials at Kings College London and led teams of volunteers in welfare and harm reduction spaces such as Kosmicare at Boom Festival in Portugal and many music festivals in the UK.
Expert Reviews & Featured Insights
News
Locked in Schedule 1. UK and the Psilocybin Question
A recent nationwide poll finds broad support for psilocybin-assisted therapy in the UK. But does…
